News | October 08, 2007

FDA Clears Endovascular System For Clot Removal

October 9, 2007 - OmniSonics Medical Technologies Inc. has received clearance from the FDA to market its catheter based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature, as the company targets the deep vein thrombosis (DVT) market.

The OmniWave Endovascular System has a minimally invasive catheter-based technology that delivers low-power, transverse ultrasonic energy designed to remove thrombus quickly, safely and effectively.

The device treats DVT, which affects approximately 2 million people in the U.S. every year, and acute limb ischemia, which affects over 250,000 people in the U.S. every year.

For more information: www.omnisonics.com


Related Content

News | Deep Vein Thrombosis (DVT)

November 21, 2022 — New research published in the Journal of the American College of Cardiology shows the use of drug ...

Home November 21, 2022
Home
News | Deep Vein Thrombosis (DVT)

November 7, 2019 — The ClotTriever Outcomes (CLOUT) Registry is evaluating real-world patient outcomes following ...

Home November 14, 2019
Home
Feature | Deep Vein Thrombosis (DVT) | Sanjay Pandya, M.D.

There are few downsides to using tibial venous access to treat deep vein thrombosis (DVT) with catheter-directed ...

Home February 16, 2018
Home
News | Deep Vein Thrombosis (DVT)

July 7, 2017 — BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular ...

Home July 07, 2017
Home
News | Deep Vein Thrombosis (DVT)

August 12, 2015 — The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help ...

Home August 12, 2015
Home
Subscribe Now